GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Amicus Therapeutics
Amicus Therapeutics specializes in treating rare genetic diseases. Its stock price is driven by the commercial success of its drugs and the results of clinical trials of new medications. The chart reflects both scientific breakthroughs and the high risks inherent in the biotech sector.
Share prices of companies in the market segment - Pharma metabolism
Amicus is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare metabolic diseases, such as Fabry and Pompe diseases. We classify it as part of the Pharma Metabolism sector, and the chart below illustrates the overall dynamics of the entire biotech industry focused on rare diseases.
Broad Market Index - GURU.Markets
Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare genetic diseases. Its focus on orphan diseases makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Amicus compares to it.
Change in the price of a company, segment, and market as a whole per day
FOLD - Daily change in the company's share price Amicus Therapeutics
Amicus Therapeutics, a rare disease-focused company, is highly volatile. Change_co measures market reaction to news about clinical trials and drug approvals. This metric is an essential component for building complex models for assessing risks and prospects in biotechnology on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Amicus Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with FOLD, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Amicus Therapeutics is a biopharmaceutical company specializing in drugs for rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Amicus's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Amicus Therapeutics
Amicus is a biotechnology company specializing in the treatment of rare genetic diseases. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Amicus Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for rare diseases. This chart shows how its success in bringing drugs to market and clinical trial results impacts its performance relative to the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Amicus Therapeutics, which specializes in drugs for rare diseases, operates in a non-cyclical sector. Demand for its drugs is unaffected by the economic climate. The company's stock performance is driven by its success in research and commercialization, making it a growth story isolated from general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Amicus Therapeutics
The value of Amicus, a biopharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its rare disease drugs, as well as news about clinical trials of its gene therapy, the success of which determines its long-term growth.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Amicus Therapeutics is a biotech company focused on developing drugs for rare metabolic diseases. Its success depends on regulatory approval and the commercial launch of new drugs. The biotech sector performance chart reflects the overall risk appetite of investors, which is an important backdrop for assessing Amicus's scientific and commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Amicus Therapeutics is a biotech company focused on treating rare genetic diseases. Its performance is unaffected by the economic climate. Amicus shares, as shown in the chart, are driven by news about clinical trials and the commercial success of its drugs, where any event can trigger a sharp move.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Amicus Therapeutics
Shares of Amicus Therapeutics, which focuses on treating rare diseases, are extremely volatile. Weekly price movements depend entirely on clinical trial results, regulatory decisions, and the commercial success of its drugs. The chart below illustrates how short-term scientific developments and investor expectations shape biotech valuations.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
How unique is Amicus Therapeutics' performance in the biotech sector? This chart compares the rare disease company's weekly stock price movements with the overall trend. This helps us understand whether its sharp movements are a unique reaction to drug news or reflect the broader sentiment of the volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Amicus Therapeutics specializes in drugs for the treatment of rare genetic diseases. This chart shows how out of sync its weekly performance is with the market. Its stock moves are driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
FOLD - Market capitalization of the company Amicus Therapeutics
Amicus Therapeutics' market capitalization reflects the company's hopes for its drugs to treat rare genetic diseases, particularly Fabry disease and Pompe disease. The company's value depends on the commercial success of its drugs. The chart illustrates how investors assess its ability to become a leader in this complex field of medicine.
FOLD - Share of the company's market capitalization Amicus Therapeutics within the market segment - Pharma metabolism
Amicus Therapeutics is a biopharmaceutical company focused on developing drugs for rare metabolic diseases. Its share of its sector market capitalization reflects the value of its approved drugs and research capabilities. The chart shows how investors view its commercial success and progress in developing new treatments.
Market capitalization of the market segment - Pharma metabolism
The chart illustrates the overall market capitalization of biotech companies focused on treating rare genetic diseases. Amicus Therapeutics is a leader in this field. The graph shows how the market values both its commercial drugs and its cutting-edge gene therapy developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with rare genetic diseases. Amicus Therapeutics' market capitalization is the market valuation of its drugs based on cutting-edge gene therapy. The line illustrates how a focus on orphan diseases and scientific innovation can create enormous value in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
FOLD - Book value capitalization of the company Amicus Therapeutics
Amicus Therapeutics' book value reflects its research capital, which is focused on fighting rare diseases. The chart below reflects the value of its drug patents, research equipment, and gene therapy manufacturing capacity. The pipeline's growth signals progress in bringing life-saving drugs to market.
FOLD - Share of the company's book capitalization Amicus Therapeutics within the market segment - Pharma metabolism
For Amicus Therapeutics, which focuses on rare diseases, its tangible assets are not giant factories, but advanced R&D centers and manufacturing facilities for creating complex biologics. The chart shows its share of this highly specialized scientific and manufacturing infrastructure.
Market segment balance sheet capitalization - Pharma metabolism
Amicus Therapeutics is a biopharmaceutical company. It not only develops but also manufactures drugs for rare diseases, making it more capital-intensive than pure R&D startups. The graph will show whether this mixed model (science and manufacturing) is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Amicus Therapeutics' balance sheet is comprised of capital invested in the development and global commercialization of drugs for the treatment of rare genetic diseases, such as Fabry disease. The company's assets include infrastructure and science aimed at helping patients neglected by big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Amicus Therapeutics
Amicus Therapeutics specializes in developing drugs for rare genetic diseases, particularly Fabry and Pompe diseases. Its market capitalization is based on the commercial success of its drugs and the prospects for future developments. The chart shows how investors value its portfolio and its leadership in treating orphan diseases.
Market to book capitalization ratio in a market segment - Pharma metabolism
Amicus Therapeutics specializes in developing drugs for rare genetic diseases. The company has approved drugs, but its valuation depends largely on future developments. The chart shows how investors value its scientific platform and drug pipeline, which represents a premium to its tangible assets.
Market to book capitalization ratio for the market as a whole
Amicus Therapeutics is a biotech company focused on developing drugs for rare diseases. The chart illustrates how the market values a company that has successfully brought its product to market. Its valuation is a combination of current sales revenue and investor confidence in the potential of its future drugs, creating a significant premium to its tangible assets.
Debts of the company, segment and market as a whole
FOLD - Company debts Amicus Therapeutics
Amicus Therapeutics is a biotechnology company focused on developing drugs for rare genetic diseases. Its leverage allows it to finance expensive clinical trials and the global launch of its drugs, bringing innovative treatments to patients worldwide.
Market segment debts - Pharma metabolism
Amicus Therapeutics is a biopharmaceutical company focused on developing drugs for rare metabolic diseases. Their strategy includes both gene therapy and traditional therapeutics. This chart shows the general financial metrics for the biotech sector, highlighting the difficulty of funding multi-platform research in this field.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Amicus Therapeutics
Amicus Therapeutics specializes in developing drugs for rare genetic diseases. The path from lab to patient is long and expensive. This chart shows how reliant the company is on external financing, including convertible debt, to advance its drugs through clinical trials and bring them to market.
Market segment debt to market segment book capitalization - Pharma metabolism
Amicus Therapeutics specializes in developing drugs for rare metabolic diseases, such as Fabry and Pompe diseases. This chart compares the company's debt, raised to fund research and drug launches, to the total market capitalization of the pharmaceutical sector. It illustrates the financial side of the fight against rare diseases.
Debt to book value of all companies in the market
Amicus Therapeutics develops drugs for rare diseases. This chart compares its debt for research to the overall book value of the entire economy. It shows how large the company's financial stakes in science are in the context of the overall size of the stock market, which is the source of its capital.
P/E of the company, segment and market as a whole
P/E - Amicus Therapeutics
This metric for Amicus Therapeutics, a biopharmaceutical company focused on treating rare diseases, reflects investors' faith in its science. The company's value is determined not so much by current profits as by the potential of its drugs to change patients' lives. The chart shows how highly the market values its developments.
P/E of the market segment - Pharma metabolism
This metric represents the average valuation for the biotech sector in which Amicus Therapeutics operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding rare disease treatments.
P/E of the market as a whole
Amicus Therapeutics is a biopharmaceutical company specializing in developing drugs to treat rare metabolic diseases such as Fabry and Pompe diseases. The company strives to bring hope to patients. This risk appetite chart helps understand how investors value biotech companies with a humanitarian mission.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Amicus Therapeutics
Amicus Therapeutics specializes in developing drugs to treat rare metabolic diseases. This chart reflects investor expectations for the commercial success of its current and future drugs. It represents the market's assessment of the company's ability to maintain a leading position in its narrow but important pharmaceutical niche.
%20P%2FE%20Amicus%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Amicus-Therapeutics&v=1772513645059 "Chart of the company's future (projected) P/E Amicus Therapeutics")
Future (projected) P/E of the market segment - Pharma metabolism
Amicus Therapeutics is a global biotech company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its primary focus is on Fabry disease and Pompe disease. This chart shows overall market sentiment toward the biotech sector, helping to assess Amicus's potential in this challenging niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772513645069 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Amicus Therapeutics is a biotechnology company specializing in developing drugs to treat rare genetic diseases. Its success depends on the commercialization of existing approved drugs and the successful development of new ones. Demand for its products is inelastic, making the business vulnerable to market cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513645086 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare metabolic diseases. Its cash flows consist of revenue from sales of its currently approved drug and significant investments in research into new drugs. This chart shows the balance between current revenue and the costs of building its future pipeline.
Profit of companies in the market segment - Pharma metabolism
Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare metabolic diseases, specifically Fabry and Pompe diseases. This chart reflects the profitability of its segment. Amicus's success depends on sales of its commercial products and clinical trial results, making it a key player shaping the dynamics of the entire niche.
Overall market profit
Amicus Therapeutics is a biopharmaceutical company focused on developing drugs for rare metabolic diseases. Its value and success are determined by clinical trial results and its ability to bring new drugs to market. This chart illustrates general economic cycles, which have little impact on Amicus's core, science-driven activities.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of rare metabolic diseases. The future profit projections reflected here depend on sales of its lead drug and the success of clinical trials of new gene therapies. This demonstrates the market's confidence in the company's potential in the field of orphan diseases.
%20profit%20of%20the%20company%20Amicus%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Amicus-Therapeutics&v=1772513645178 "Graph of future (projected) profit of the company Amicus Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Amicus Therapeutics is a global biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. This chart shows profitability projections for this pharmaceutical segment. It reflects expectations for the commercial success of the company's existing and future drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772513645181 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Amicus Therapeutics is a biopharmaceutical company focused on treating rare genetic diseases. The company's success depends on scientific breakthroughs and regulatory approvals. The overall earnings outlook reflected here influences investor sentiment. A positive market environment facilitates the significant capital Amicus needs to bring its innovative drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513645199 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on treating rare genetic diseases. With commercialized products, the P/S ratio is becoming an important indicator. It shows how investors view the company's drug sales growth and the potential of its research platform.
P/S market segment - Pharma metabolism
Amicus Therapeutics is a biopharmaceutical company specializing in developing drugs to treat rare genetic diseases, specifically Fabry and Pompe diseases. Their success depends on the commercialization of these drugs. The chart shows how the market values their orphan drug portfolio and their potential to become a leader in the treatment of rare diseases.
P/S of the market as a whole
Amicus Therapeutics specializes in developing drugs for rare metabolic diseases. The company's revenue is generated through sales of its approved drugs and grows as their use expands. This chart shows the average revenue estimate, which helps understand the market premium for revenue in the orphan disease niche.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Amicus Therapeutics
Amicus Therapeutics specializes in developing drugs to treat rare metabolic diseases, such as Fabry disease. This chart shows investor expectations for future sales of its key drug and the potential for new developments targeting patients with rare genetic disorders, where there is a high unmet need.
%20P%2FS%20Amicus%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Amicus-Therapeutics&v=1772513645276 "The graph of the company's future (projected) P/S Amicus Therapeutics")
Future (projected) P/S of the market segment - Pharma metabolism
Amicus Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare metabolic diseases, specifically Fabry disease and Pompe disease. This chart shows how the market assesses the future commercial potential of its drugs compared to other companies working on rare diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772513645283 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Amicus Therapeutics is a biotech company specializing in the treatment of rare genetic diseases. Its strategy is based on a deep scientific understanding of these diseases. This chart shows overall revenue projections, and Amicus illustrates how investors' faith in science and the ability to create breakthrough treatments for small patient populations drives value in the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513645299 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare metabolic diseases, specifically Fabry disease and Pompe disease. This chart shows the revenue from sales of its already approved drugs. Sales growth is directly dependent on expanding patient access to these therapies worldwide.
Sales of companies in the market segment - Pharma metabolism
Amicus Therapeutics is a biotech company focused on treating rare metabolic diseases. This chart segments its revenue by key drugs, such as Galafold. It allows investors to track sales trends and assess the commercial success of its innovative treatments.
Overall market sales
Amicus Therapeutics is a biopharmaceutical company focused on developing drugs to treat rare metabolic diseases. Its success depends on scientific breakthroughs and market access, not economic cycles. This chart is not relevant to the valuation of Amicus, whose value is created in the laboratory and clinical trials, not in the general market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Amicus Therapeutics
Amicus Therapeutics specializes in developing drugs to treat rare metabolic diseases, such as Fabry and Pompe diseases. Its revenue forecast depends on the successful commercialization of its drugs. This chart shows how analysts assess the potential of its therapies and their ability to capture market share in orphan diseases.
%20sales%20of%20the%20company%20Amicus%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Amicus-Therapeutics&v=1772513645355 "Schedule of future (projected) sales of the company Amicus Therapeutics")
Future (projected) sales of companies in the market segment - Pharma metabolism
Amicus Therapeutics specializes in developing drugs to treat rare metabolic diseases. This chart shows projected revenue for this pharmaceutical segment. It allows investors to assess the size and growth prospects of this niche market, which is critical for the commercial prospects of Amicus' innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772513645370 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Amicus Therapeutics is a biotechnology company focused on developing treatments for rare genetic diseases. Demand for its products is driven by medical needs. However, the overall market environment, shown in the chart, influences investor sentiment and their willingness to finance long-term, risky projects in the biotechnology sector, which is important for the company.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513645381 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Amicus Therapeutics
Amicus Therapeutics is a biotechnology company focused on developing drugs for rare genetic diseases. This graph shows the path from scientific discovery to commercial success. The company's ability to convert revenue into profit is directly dependent on successful sales of its drugs and the efficient management of its extensive research and development costs.
Market segment marginality - Pharma metabolism
Amicus Therapeutics is a biotech company focused on developing drugs for rare genetic diseases. This chart shows the commercial return on its efforts. High profitability reflects the company's successful launch of life-changing drugs and strong patent protection.
Market marginality as a whole
Amicus Therapeutics specializes in developing drugs for the treatment of rare metabolic diseases. The company already has commercial products and continues research. This overall profitability chart shows average growth, while Amicus operates in a niche where the success of a single drug can drive sustainable growth for many years.
Employees in the company, segment and market as a whole
Number of employees in the company Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing drugs for rare metabolic diseases. The growth of its team, particularly in its commercial division, is a direct result of the successful launch of its drugs. This graph shows the transition from R&D to full-fledged commercial operations.
Share of the company's employees Amicus Therapeutics within the market segment - Pharma metabolism
Amicus Therapeutics is a global biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. This chart highlights its scientific focus. It reflects the proportion of leading geneticists and researchers working on treating diseases like Fabry disease that Amicus brings together.
Number of employees in the market segment - Pharma metabolism
Amicus Therapeutics is a biopharmaceutical company focused on developing drugs to treat rare metabolic diseases. This chart illustrates employment in the metabolic research sector. The growing number of scientists in this niche demonstrates progress in understanding and treating rare genetic diseases, which is Amicus' core mission.
Number of employees in the market as a whole
Amicus Therapeutics is a biopharmaceutical company specializing in the treatment of rare genetic diseases. The growth of its scientific and commercial teams is directly linked to the approval and launch of new drugs. This is an example of how years of research translates into real cures, jobs, and hope for patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Amicus Therapeutics (FOLD)
Amicus Therapeutics is a biotech company focused on treating rare genetic diseases. Their value is determined by both sales of existing drugs and the potential of their developments. This chart shows that even for a commercial biotech company, the market capitalization per employee remains very high due to the enormous value of their intellectual property.
%20of%20the%20company%20Amicus%20Therapeutics%20(FOLD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Amicus-Therapeutics-FOLD&v=1772513645455 "Chart of market capitalization per employee (in thousands of dollars) of the company Amicus Therapeutics (FOLD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Amicus is a biotech company focused on treating rare genetic diseases (Fabry disease, Pompe disease). They have approved drugs. This chart shows the industry average. It helps assess how the market views their commercial success and R&D platform in this complex niche, based on per-employee ratio.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772513645470 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Amicus Therapeutics is a biotech company focused on developing drugs for rare genetic diseases. The company's value is determined by its scientific portfolio. This chart reflects investors' belief in the team's ability to create and commercialize life-changing treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513645485 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Amicus Therapeutics (FOLD)
Amicus Therapeutics is a biotech company focused on treating rare metabolic diseases (such as Pompe disease). The company has commercially available drugs. This chart shows how successfully the company sells its very expensive, niche drugs and whether their revenues cover R&D and personnel costs.
%20Chart%20Amicus%20Therapeutics%20(FOLD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Amicus-Therapeutics-FOLD&v=1772513645507 "Company Profit Per Employee (in thousands of dollars) Chart Amicus Therapeutics (FOLD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Amicus Therapeutics is a biotech company specializing in the treatment of rare metabolic diseases (Fabry disease). This chart shows the benchmark for "Specialty Pharma." In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high (when a blockbuster drug is approved).
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772513645514 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Amicus Therapeutics is a biopharmaceutical company specializing in developing drugs for rare metabolic diseases (Fabry disease, Pompe disease). This is R&D for orphan diseases. This indicator, which shows the average contribution of one employee to profit, asks the question: how does this biotech sector compare to average profitability?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513645517 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Amicus Therapeutics (FOLD)
Amicus Therapeutics, a biopharmaceutical company focused on rare diseases, demonstrates the success of its drug commercialization in this chart. The high revenue per employee reflects the high cost of innovative drugs and the company's ability to effectively operate in niche markets that require deep expertise.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Amicus-Therapeutics-FOLD&v=1772513645521 "Sales chart per company employee Amicus Therapeutics (FOLD)")
Sales per employee in the market segment - Pharma metabolism
Amicus Therapeutics is a biotech company focused on treating rare diseases, particularly Fabry disease. The company has commercially available drugs. This chart shows the average revenue per employee in this segment. It allows one to assess how productive Amicus's team (both scientific and commercial) is compared to other biotech companies in this niche.
Sales per employee for the market as a whole
Amicus Therapeutics (FOLD) is a biotech company focused on treating rare diseases (such as Pompe disease). The company has commercial drugs. This chart shows how successfully their commercial team is selling these highly specialized and very expensive drugs, monetizing their years of R&D investment.
Short shares by company, segment and market as a whole
Shares shorted by company Amicus Therapeutics (FOLD)
Amicus Therapeutics is a biotech company specializing in the treatment of rare metabolic diseases, specifically Fabry disease and Pompe disease. This chart highlights concerns about their commercial success. Bears are betting that their drugs will face stiff competition or that their market launches will be slower than expected.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Amicus-Therapeutics-FOLD&v=1772513645548 "Short Shares Chart for the Company Amicus Therapeutics (FOLD)")
Shares shorted by market segment - Pharma metabolism
Amicus Therapeutics is a biotech company specializing in the treatment of rare metabolic diseases, particularly Fabry disease. This chart highlights the pessimism in the biotech sector. The rise in short positions across the industry reflects investor concerns about competition in the orphan drug market or challenges in increasing sales of approved drugs.
Shares shorted by the overall market
Amicus Therapeutics (FOLD) is a biopharmaceutical company focused on developing and commercializing drugs to treat rare metabolic diseases, such as Fabry disease. This chart illustrates the overall market pessimism. Demand for rare disease drugs is typically stable, but for a company that may not yet be profitable, rising market fears complicate access to capital and weigh on its valuation.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Amicus Therapeutics (FOLD)
Amicus Therapeutics focuses on developing drugs to treat rare genetic diseases. The stock is volatile and dependent on R&D. A price above 70 may reflect positive trial data or FDA approval. Oversold territory (<30) is often associated with research setbacks or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Amicus-Therapeutics-FOLD&v=1772513645590 "RSI 14 indicator chart for the company's stock Amicus Therapeutics (FOLD)")
RSI 14 Market Segment - Pharma metabolism
Amicus Therapeutics is a biopharmaceutical company specializing in rare metabolic diseases. Its lead product is a drug for the treatment of Pompe disease and a therapy for Fabry disease. This chart shows the overall sentiment in the rare metabolic disease biotech sector. It helps separate the FOLD trend from the general "noise" in the biotech sector.
RSI 14 for the overall market
Amicus Therapeutics (FOLD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast FOLD (Amicus Therapeutics)
Amicus Therapeutics (FOLD) is a biopharmaceutical company specializing in the treatment of rare (orphan) diseases. Its main product is Galafold, a treatment for Fabry disease. The chart shows the average Wall Street forecast, reflecting analyst expectations for sales growth for Galafold and the successful launch of a new drug for Pompe disease.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FOLD-Amicus-Therapeutics&v=1772513645665 "A chart showing analyst consensus forecasts for the expected stock price. FOLD (Amicus Therapeutics)")
The difference between the consensus estimate and the actual stock price FOLD (Amicus Therapeutics)
Amicus Therapeutics is a biotech company focused on treating rare metabolic diseases, primarily Pompe disease and Fabry disease. This chart shows the gap between the current market valuation and analyst target price. It highlights the potential experts see in their commercial drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FOLD-Amicus-Therapeutics&v=1772513645717 "A chart showing the difference between the consensus forecast and the actual stock price. FOLD (Amicus Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Amicus Therapeutics is a biotech company focused on orphan diseases, primarily Fabry disease and Pompe disease. This chart shows analysts' overall expectations for the metabolic pharma sector. It reflects whether experts believe in the commercial success of drugs for rare diseases.
Analysts' consensus forecast for the overall market share price
Amicus Therapeutics (FOLD) is an R&D biotech focused on rare (orphan) genetic diseases (Fabry, Pompe). This graph, reflecting expert expectations, influences them. During a recession (pessimism), insurers (payers) put downward pressure on prices, even on orphan (ultra-expensive) drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Amicus Therapeutics
Amicus is a biotech company focused on treating rare (orphan) genetic diseases, primarily Pompe disease and Fabry disease. This chart is an indicator of their commercialization. It likely aggregates the sales growth rate of their drugs and the market assessment of their ability to successfully commercialize therapies for these complex diseases.
AKIMA Market Segment Index - Pharma metabolism
Amicus (FOLD) is a biotech focused on rare (orphan) diseases; the company is a leader in the treatment of Fabry disease and Pompe disease. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does FOLD's niche (rare disease) R&D strategy differentiate it from the average pharma company?
The AKIM Index for the overall market
Amicus is a commercial-stage biotech company focused on rare genetic diseases (Fabry disease, Pompe disease). It's a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding companies like Amicus.
